Bracco Imaging is launching AiMIFY, an AI-powered contrast-enhancement software developed with Subtle Medical, in the European Union (EU), and has announced a strategic partnership on contrast-enhanced CT with Avicenna.AI.
AiMIFY amplifies contrast enhancement in brain MR images acquired after injection of a gadolinium-based contrast agent, to support radiologists in detecting and assessing brain lesions, according to the company.
The collaboration with Avicenna.AI will focus on computer-assisted detection and diagnosis in brain CT angiography, Bracco said. The solution is currently in development and clinical validation at sites in the U.S. and Europe, with a U.S. Food and Drug Administration submission planned for the second half of 2026.
Both collaborations will be featured at ECR 2026 in Vienna, Austria.
![Axial images from unenhanced calcium score cardiac CT (left) and curved planar reformation images from CT angiography (right) show that higher long-term exposure to air pollution is associated with greater coronary artery calcium and more obstructive coronary artery disease (CAD). Top row: Images in a 68-year-old male patient with higher 10-year mean ambient air pollution exposure (7.9 μg/m3 for particulate matter measuring ≤2.5 μm in diameter [PM2.5] and 17.4 parts per billion [ppb] for NO2) with extensive CAD (coronary artery calcium score [CACS] >1,000 and obstructive CAD [≥70% diameter stenosis]). Bottom row: Images in a 57-year-old female patient with lower 10-year mean ambient air pollution exposure (6.3 μg/m3 for PM2.5 and 4.6 ppb for NO2) with no CAD (CACS = 0 and no obstructive stenosis).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/06/hanneman.r6SMLzkezo.png?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
